CYCN - Cyclerion Therapeutics Inc.: 52-Week High Recently Eclipsed (CYCN)
Shares of Cyclerion Therapeutics Inc. (NASDAQ:CYCN) traded today at $21.89, eclipsing its 52-week high. So far today approximately 36.2 million shares have been exchanged, as compared to an average 30-day volume of 118,000 shares.
In the past 52 weeks, shares of Cyclerion Therapeutics Inc. have traded between a low of $0.90 and a high of $21.89 and is now at $1.19, which is 32% above that low price.
Cyclerion Therapeutics Inc. (NASDAQ:CYCN) defies analysts with a current price ($1.19) 9.9% above its average consensus price target of $1.07.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
Receive IBN Spotlights - "Bite Size" Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About IBN (InvestorBrandNetwork)
IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.
For more information on IBN, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer